Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 1/20 | 0.77 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.77 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.77 |
| ▸ | CTSL | P07711 | 9/20 | 0.72 |
| ▸ | CTSB | P07858 | 6/20 | 0.72 |
| ▸ | CTSK | P43235 | 5/20 | 0.69 |
| ▸ | CTSS | P25774 | 2/20 | 0.65 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mg-132 SCHEMBL13436259 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL160925 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL10006388 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL14579851 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL2522088 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL5062219 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL2535252 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL14514061 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| SCHEMBL7710728 | 0.99 | PSMB1 (0.78) | PSMB1PSMB5PSMB2CTSLCTSB | |
| SCHEMBL3054703 | 0.99 | PSMB1 (0.78) | PSMB1PSMB5PSMB2CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021178-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS AG (CH) | 2026-01-22 | — | — | US | disclosed |
| EP-3265112-B1 | UBIQUITIN LIGASE KPC1 AND P50 FOR USE IN THE TREATMENT OF CANCER | TECHNION RES & DEV FOUNDATION (IL) | 2025-12-24 | — | — | EP | disclosed |
| US-12454564-B2 | Compositions and methods for T cell engineering | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2025-10-28 | — | — | US | disclosed |
| US-20250236671-A1 | CD229 Car T Cells And Methods Of Use Thereof | UNIV UTAH RES FOUND (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4578507-A2 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | Gracell Biotechnologies (Shanghai) Co., Ltd. (CN) | 2025-07-02 | — | — | EP | disclosed |
| EP-3874030-B1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | GRACELL BIOTECHNOLOGIES SHANGHAI CO LTD (CN) | 2025-03-12 | — | — | EP | disclosed |
| US-20240352123-A1 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | UNIV UTAH RES FOUND (US) | 2024-10-24 | — | — | US | disclosed |
| EP-4441085-A2 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | University of Utah Research Foundation (US) | 2024-10-09 | — | — | EP | disclosed |
| US-11952428-B2 | BCMA chimeric antigen receptors and uses thereof | NOVARTIS AG (CH) | 2024-04-09 | — | — | US | disclosed |
| US-11939389-B2 | BCMA chimeric antigen receptors and uses thereof | NOVARTIS AG (CH) | 2024-03-26 | — | — | US | disclosed |
| US-20170340733-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2017-11-30 | — | — | US | disclosed |
| US-20170296659-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2017-10-19 | — | — | US | disclosed |
| US-20170281624-A1 | COMBINATION THERAPIES OF ALK INHIBITORS | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20170209574-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2017-07-27 | — | — | US | disclosed |
| EP-3191097-A1 | COMBINATION THERAPIES | Novartis AG (CH) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016116922-A1 | UBIQUITIN LIGASE KPC1 PROMOTES PROCESSING OF P105 NF-KAPPAB1 TO P50, ELICITING STRONG TUMOR SUPPRESSION | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016040892-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2016-03-17 | — | — | WO | disclosed |
| US-20160046724-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-18 | — | — | US | disclosed |
| US-7989495-B2 | 3-Sulfonyl propenenitriles, e.g., BAY 11-7085 (3-(t-butylphenylsulfonyl)-2-propenenitrile; promoting apoptosis and inhibiting readhesion of cancer cells; antimetastasis agents, particularly for hepatic, parietal or peritoneal area; inhibiting tumorigenesis; antiproliferative agents (not for myeloma) | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1153612-A1 | ANTICANCER AGENT POTENTIATORS | Tsuruo, Takashi (US) | 2001-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170296659-A1 | COMBINATION THERAPIES | MET, BRAF, ERBB2 | PSMB1 2828/4885PSMB5 3246/4885PSMB2 2468/4885 |
| US-20170340733-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | PSMB1 4455/4885PSMB5 4311/4885PSMB2 3467/4885 |
| US-11939389-B2 | BCMA chimeric antigen receptors and uses thereof | TNFRSF9, CD40, BCR | PSMB1 3908/4885PSMB5 2404/4885PSMB2 4508/4885 |
| US-20160046724-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR | TNFRSF9, CD40, BCR | PSMB1 3358/4885PSMB5 1815/4885PSMB2 4251/4885 |
| US-11952428-B2 | BCMA chimeric antigen receptors and uses thereof | TNFRSF9, CD40, BCR | PSMB1 3908/4885PSMB5 2404/4885PSMB2 4508/4885 |
| US-20250236671-A1 | CD229 Car T Cells And Methods Of Use Thereof | CD2, CD2BP2, CD22 | PSMB1 4097/4885PSMB5 4539/4885PSMB2 4244/4885 |
| US-20170209574-A1 | COMBINATION THERAPIES | CD274, CD40, CD58 | PSMB1 1877/4885PSMB5 3092/4885PSMB2 2404/4885 |
| US-20260021178-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | GSAP, BACE1, CD79B | PSMB1 206/4885PSMB5 734/4885PSMB2 547/4885 |
| US-20240352123-A1 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | CD2BP2, CD2, CD22 | PSMB1 3022/4885PSMB5 3700/4885PSMB2 3745/4885 |
| US-20170281624-A1 | COMBINATION THERAPIES OF ALK INHIBITORS | ALK, CD274, PDCD1LG2 | PSMB1 3574/4885PSMB5 4359/4885PSMB2 3663/4885 |
| US-12454564-B2 | Compositions and methods for T cell engineering | PBK, CD47, MICA | PSMB1 1695/4885PSMB5 2540/4885PSMB2 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.